Marker Therapeutics (NASDAQ:MRKR) Trading Up 8.3% – Here’s What Happened

by · The Cerbat Gem

Marker Therapeutics, Inc. (NASDAQ:MRKR – Get Free Report) was up 8.3% on Friday . The stock traded as high as $3.53 and last traded at $3.52. Approximately 17,599 shares traded hands during mid-day trading, a decline of 28% from the average daily volume of 24,576 shares. The stock had previously closed at $3.25.

Marker Therapeutics Stock Up 8.3 %

The company has a fifty day moving average price of $3.09 and a two-hundred day moving average price of $3.99.

Marker Therapeutics (NASDAQ:MRKR – Get Free Report) last issued its earnings results on Wednesday, August 14th. The company reported ($0.25) earnings per share (EPS) for the quarter. Marker Therapeutics had a negative net margin of 278.27% and a negative return on equity of 78.91%. The firm had revenue of $1.17 million during the quarter. On average, sell-side analysts expect that Marker Therapeutics, Inc. will post -1.43 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Marker Therapeutics

A hedge fund recently raised its stake in Marker Therapeutics stock. Wedbush Securities Inc. lifted its stake in Marker Therapeutics, Inc. (NASDAQ:MRKR – Free Report) by 52.7% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 69,500 shares of the company’s stock after buying an additional 24,000 shares during the period. Wedbush Securities Inc. owned approximately 0.78% of Marker Therapeutics worth $377,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 22.39% of the company’s stock.

About Marker Therapeutics

(Get Free Report)

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens.

Further Reading